DOCSLIB.ORG

An Overview of Acute Myeloid Leukemia and Cancer Immunology: (I) Concepts and Therapeutic Strategies and (Ii) Repsox As a Candidate Cell-Engineering Tool

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
An Overview of Acute Myeloid Leukemia and Cancer Immunology: (I) Concepts and Therapeutic Strategies and (Ii) Repsox As a Candidate Cell-Engineering Tool Graduate Theses, Dissertations, and Problem Reports 2014 An Overview of Acute Myeloid Leukemia and Cancer Immunology: (i) Concepts and Therapeutic Strategies and (ii) RepSox as a Candidate Cell-Engineering Tool Audrey Nadine Jajosky Follow this and additional works at: https://researchrepository.wvu.edu/etd Recommended Citation Jajosky, Audrey Nadine, "An Overview of Acute Myeloid Leukemia and Cancer Immunology: (i) Concepts and Therapeutic Strategies and (ii) RepSox as a Candidate Cell-Engineering Tool" (2014). Graduate Theses, Dissertations, and Problem Reports. 5874. https://researchrepository.wvu.edu/etd/5874 This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses, Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. For more information, please contact [email protected]. An Overview of Acute Myeloid Leukemia and Cancer Immunology: (i) Concepts and Therapeutic Strategies and (ii) RepSox as a Candidate Cell-Engineering Tool Audrey Nadine Jajosky Dissertation submitted to the West Virginia University School of Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy In Cancer Cell Biology Michael Ruppert, MD, PhD, Chair Linda Vona-Davis, PhD Steven Frisch, PhD Karen Martin, PhD William Tse, MD Laura F. Gibson, PhD, mentor Cancer Cell Biology Program Morgantown, West Virginia 2014 Key words: RepSox (E 616452), acute myeloid leukemia (AML), CD34+ AML cells, Tim-3, CXCL12 (SDF-1), cancer immunotherapy, TGF-β, c-Myc, CXCR4, CXCR7, γ9δ2 T cells, reprogramming, cell engineering, co-culture, cancer stem cells, immunogenicity, immunologic synapse, aldehyde dehydrogenase (ALDH), ALK5 ABSTRACT An Overview of Acute Myeloid Leukemia and Cancer Immunology: (i) Concepts and Therapeutic Strategies and (ii) RepSox as a Candidate Cell-Engineering Tool Audrey Nadine Jajosky This dissertation is intentionally broad in scope and describes the conceptual frameworks, research advances, and clinical successes that inspired a therapeutic vision that, in turn, prompted specific RepSox experiments (Jajosky, 2014). The goal of this dissertation is to guide and encourage students interested in engineering anti-cancer immune therapies by providing perspective and suggestions. Chapter I provides background on acute myeloid leukemia (AML), the cancer stem cell (CSC) theory, and the chemical reprogramming tool “RepSox.” Chapter II describes how tumor cells passively evade immune recognition and actively suppress immune cells to escape destruction. Immunotherapeutic strategies are described that increase tumor-cell immunogenicity and/or sensitize tumor cells to immune-mediated death. Chapter III reviews immune-cell defects induced by cancer-distorted microenvironments. Tumor cells alter local physical and metabolic conditions and distort surrounding stromal cells in ways that impair infiltrating immune cells and promote cancer progression. Strategies are described that can reverse immune-cell defects and improve anti-tumor immunity. Chapter IV highlights successful cancer immunotherapies, including patient-specific, FDA-approved, and AML leukemic stem cell (LSC)-targeted strategies. These therapies involve antibodies, activated immune cells, and/or immuno-modulatory agents designed to eradicate tumor cells, repair and activate dysfunctional immune cells, and reduce cancer-induced immune suppression in tumor microenvironments. Chapter V describes the features and rationale of a therapeutic vision that, in combination with recent clinical and research findings, guided this project and identified specific technical obstacles. Chapter VI is the published study – entitled “RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression” – which describes how RepSox, a “small molecule” reprogramming tool and TGF-β inhibitor, affects AML cells. The key findings are RepSox (1) slows decay of primary CD34+ AML cells from patients with diverse AML disease, (2) increases CXCL12 and MYC, and (3) accelerates loss of Tim-3, an inhibitory (immune-checkpoint) receptor, from the surface of AML cells. Thus, RepSox may promote in vitro engineering of patient-specific AML LSC-targeted therapies by prolonging survival of primitive CD34+ AML cells and increasing AML-cell immunogenicity via Tim-3 reduction. When envisioning the immunologic synapse between antigen- presenting AML cells and T cells, the actions of RepSox suggest RepSox might promote in vitro T-cell activation against primitive (relapse-causing) AML cells which represent the most problematic therapeutic target. Chapter VII discusses the potential therapeutic applications of these results in the context of AML and other cancers as well as unanswered questions and future research options. For example, the actions of RepSox suggest that its incorporation into pre-existing co-culture methods that exploit TCR agonists may enhance the activation of γδ T cells against a patient’s primitive AML cells and, thereby, help generate more effective immune-cell therapies. One goal of this dissertation is to encourage students to integrate new findings and conceptual frameworks from immunology, regenerative medicine, and cancer research when deciding which exciting research agendas to pursue. DEDICATION This project was sustained by reviewing, as needed, fascinating stories about past cancer fighters – like those remarkable volunteers in the "Women's Field Army" (1936) immortalized by their "sword of hope" – and by receiving support from the optimistic and creative students and faculty at West Virginia University. In my future endeavors as a physician-scientist, I hope to honor the memory of NCI’s Dr. Alessandra Margherita Bini whose death – by cancer – prevented me from thanking her for four years of NIH support. i ACKNOWLEDGMENTS Patients treated at WVU’s Mary Babb Randolph Cancer Center donated their leukemia specimens so this research could be conducted. To them I am indebted, and I intend to “pay their altruism forward.” My mentor, Dr. Laura Gibson, members of my PhD committee, Dr. Linda Vona-Davis, Dr. Steven Frisch, Dr. Karen Martin, Dr. Michael Ruppert, Dr. William Tse, and Dr. Fred Minnear were helpful in ways that went beyond insightful suggestions and guidance. Most notably, they fostered a creative environment that inspired me to “have no fear,” design my own project, and have it critiqued by experts at the National Cancer Institute (NCI). For four years, a sense of gratitude for the NCI grant award motivated me – especially when working in the lab at 3-am. Cancer researchers at NCI felt I had potential, and I am grateful. At WVU, the examples set by clinicians and scientists showed me how to collaborate and have fun while learning from others. Staff in the Gibson lab, WVU's Pathology Department, and flow cytometry and imaging facilities provided not just technical help but laughs and wonderful memories that make me smile. WVU's “Osborn Program” retreats reminded me that patients are the reason we work as hard as we do and that human suffering engenders a sense of urgency that can drive the creativity that helps us solve technical problems. Daniel Vanderbilt, my MD-PhD classmate, has been a wonderful friend. His constant support, commitment to science, and words of encouragement have inspired and comforted me. Overall, I am impressed by how the MD-PhD community at WVU has succeeded in creating a nurturing and creative intellectual environment. I am grateful to the patients, scientists, physicians, staff, students – and supportive neighbors – for all the fun and laughs in Morgantown, a truly exciting “college town.” Go Mountaineers! ii TABLE OF CONTENTS Dedication ........................................................................................................................ i Acknowledgements .......................................................................................................... ii Table of contents ............................................................................................................. iii List of abbreviations ....................................................................................................... vii List of tables .................................................................................................................... x List of figures ................................................................................................................... xi Preface .................................................................................................................................... 1 Chapter I: Background on Acute Myeloid Leukemia, the Cancer Stem Cell Theory, and the TGF-β inhibitor “RepSox” ...................................................................................... 3 Pathogenesis ........................................................................................................ 4 Subtypes .............................................................................................................
Load more

Recommended publications
  • Updates in Mastocytosis
    Updates in Mastocytosis Tryptase PD-L1 Tracy I. George, M.D. Professor of Pathology 1 Disclosure: Tracy George, M.D. Research Support / Grants None Stock/Equity (any amount) None Consulting Blueprint Medicines Novartis Employment ARUP Laboratories Speakers Bureau / Honoraria None Other None Outline • Classification • Advanced mastocytosis • A case report • Clinical trials • Other potential therapies Outline • Classification • Advanced mastocytosis • A case report • Clinical trials • Other potential therapies Mastocytosis symposium and consensus meeting on classification and diagnostic criteria for mastocytosis Boston, October 25-28, 2012 2008 WHO Classification Scheme for Myeloid Neoplasms Acute Myeloid Leukemia Chronic Myelomonocytic Leukemia Atypical Chronic Myeloid Leukemia Juvenile Myelomonocytic Leukemia Myelodysplastic Syndromes MDS/MPN, unclassifiable Chronic Myelogenous Leukemia MDS/MPN Polycythemia Vera Essential Thrombocythemia Primary Myelofibrosis Myeloproliferative Neoplasms Chronic Neutrophilic Leukemia Chronic Eosinophilic Leukemia, NOS Hypereosinophilic Syndrome Mast Cell Disease MPNs, unclassifiable Myeloid or lymphoid neoplasms Myeloid neoplasms associated with PDGFRA rearrangement associated with eosinophilia and Myeloid neoplasms associated with PDGFRB abnormalities of PDGFRA, rearrangement PDGFRB, or FGFR1 Myeloid neoplasms associated with FGFR1 rearrangement (EMS) 2017 WHO Classification Scheme for Myeloid Neoplasms Chronic Myelomonocytic Leukemia Acute Myeloid Leukemia Atypical Chronic Myeloid Leukemia Juvenile Myelomonocytic
    [Show full text]
  • Old and New Challenges in Uveitis Associated with Behçet's Disease
    Journal of Clinical Medicine Review Old and New Challenges in Uveitis Associated with Behçet’s Disease Julie Gueudry 1,* , Mathilde Leclercq 2, David Saadoun 3,4,5 and Bahram Bodaghi 6 1 Department of Ophthalmology, Hôpital Charles Nicolle, F-76000 Rouen, France 2 Department of Internal Medicine, Hôpital Charles Nicolle, F-76000 Rouen, France; [email protected] 3 Department of Internal Medicine and Clinical Immunology, AP-HP, Centre National de Références Maladies Autoimmunes et Systémiques Rares et Maladies Autoinflammatoires Rares, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, France; [email protected] 4 Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMR S 959, Immunology-Immunopathology-Immunotherapy (I3), F-75005 Paris, France 5 Biotherapy (CIC-BTi), Hôpital Pitié-Salpêtrière, AP-HP, F-75651 Paris, France 6 Department of Ophthalmology, IHU FOReSIGHT, Sorbonne-AP-HP, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, France; [email protected] * Correspondence: [email protected]; Tel.: +33-2-32-88-80-57 Abstract: Behçet’s disease (BD) is a systemic vasculitis disease of unknown origin occurring in young people, which can be venous, arterial or both, classically occlusive. Ocular involvement is particularly frequent and severe; vascular occlusion secondary to retinal vasculitis may lead to rapid and severe loss of vision. Biologics have transformed the management of intraocular inflammation. However, the diagnosis of BD is still a major challenge. In the absence of a reliable biological marker, diagnosis is based on clinical diagnostic criteria and may be delayed after the appearance of the onset sign. However, therapeutic management of BD needs to be introduced early in order to control inflammation, to preserve visual function and to limit irreversible structural damage.
    [Show full text]
  • Late Effects Among Long-Term Survivors of Childhood Acute Leukemia in the Netherlands: a Dutch Childhood Leukemia Study Group Report
    0031-3998/95/3805-0802$03.00/0 PEDIATRIC RESEARCH Vol. 38, No.5, 1995 Copyright © 1995 International Pediatric Research Foundation, Inc. Printed in U.S.A. Late Effects among Long-Term Survivors of Childhood Acute Leukemia in The Netherlands: A Dutch Childhood Leukemia Study Group Report A. VAN DER DOES-VAN DEN BERG, G. A. M. DE VAAN, J. F. VAN WEERDEN, K. HAHLEN, M. VAN WEEL-SIPMAN, AND A. J. P. VEERMAN Dutch Childhood Leukemia Study Group,' The Hague, The Netherlands A.8STRAC ' Late events and side effects are reported in 392 children cured urogenital, or gastrointestinal tract diseases or an increased vul­ of leukemia. They originated from 1193 consecutively newly nerability of the musculoskeletal system was found. However, diagnosed children between 1972 and 1982, in first continuous prolonged follow-up is necessary to study the full-scale late complete remission for at least 6 y after diagnosis, and were effects of cytostatic treatment and radiotherapy administered treated according to Dutch Childhood Leukemia Study Group during childhood. (Pediatr Res 38: 802-807, 1995) protocols (70%) or institutional protocols (30%), all including cranial irradiation for CNS prophylaxis. Data on late events (relapses, death in complete remission, and second malignancies) Abbreviations were collected prospectively after treatment; late side effects ALL, acute lymphocytic leukemia were retrospectively collected by a questionnaire, completed by ANLL, acute nonlymphocytic leukemia the responsible pediatrician. The event-free survival of the 6-y CCR, continuous first complete remission survivors at 15 y after diagnosis was 92% (±2%). Eight late DCLSG, Dutch Childhood Leukemia Study Group relapses and nine second malignancies were diagnosed, two EFS, event free survival children died in first complete remission of late toxicity of HR, high risk treatment, and one child died in a car accident.
    [Show full text]
  • Where Do Novel Drugs of 2016 Fit In?
    FORMULARY JEOPARDY: WHERE DO NOVEL DRUGS OF 2016 FIT IN? Maabo Kludze, PharmD, MBA, CDE, BCPS, Associate Director Elizabeth A. Shlom, PharmD, BCPS, SVP & Director Clinical Pharmacy Program Acurity, Inc. Privileged and Confidential August 15, 2017 Privileged and Confidential Program Objectives By the end of the presentation, the pharmacist or pharmacy technician participant will be able to: ◆ Identify orphan drugs and first-in-class medications approved by the FDA in 2016. ◆ Describe the role of new agents approved for use in oncology patients. ◆ Identify and discuss the role of novel monoclonal antibodies. ◆ Discuss at least two new medications that address public health concerns. Neither Dr. Kludze nor Dr. Shlom have any conflicts of interest in regards to this presentation. Privileged and Confidential 2016 NDA Approvals (NMEs/BLAs) ◆ Nuplazid (primavanserin) P ◆ Adlyxin (lixisenatide) ◆ Ocaliva (obeticholic acid) P, O ◆ Anthim (obitoxaximab) O ◆ Rubraca (rucaparib camsylate) P, O ◆ Axumin (fluciclovive F18) P ◆ Spinraza (nusinersen sodium) P, O ◆ Briviact (brivaracetam) ◆ Taltz (ixekizumab) ◆ Cinqair (reslizumab) ◆ Tecentriq (atezolizumab) P ◆ Defitelio (defibrotide sodium) P, O ◆ Venclexta (venetoclax) P, O ◆ Epclusa (sofosburvir and velpatasvir) P ◆ Xiidra (lifitigrast) P ◆ Eucrisa (crisaborole) ◆ Zepatier (elbasvir and grazoprevir) P ◆ Exondys 51 (eteplirsen) P, O ◆ Zinbyrta (daclizumab) ◆ Lartruvo (olaratumab) P, O ◆ Zinplava (bezlotoxumab) P ◆ NETSTPOT (gallium Ga 68 dotatate) P, O O = Orphan; P = Priority Review; Red = BLA Privileged and Confidential History of FDA Approvals Privileged and Confidential Orphan Drugs ◆FDA Office of Orphan Products Development • Orphan Drug Act (1983) – drugs and biologics . “intended for safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the U.S.
    [Show full text]
  • Review Anti-Cytokine Biologic Treatment Beyond Anti-TNF in Behçet's Disease
    Review Anti-cytokine biologic treatment beyond anti-TNF in Behçet’s disease A. Arida, P.P. Sfikakis First Department of Propedeutic Internal ABSTRACT and thrombotic complications (1-3). Medicine Laikon Hospital, Athens, Unmet therapeutic needs in Behçet’s Treatment varies according to type and University Medical School, Greece. disease have drawn recent attention to severity of disease manifestations. Cor- Aikaterini Arida, MD biological agents targeting cytokines ticosteroids, interferon-alpha and con- Petros P. Sfikakis, MD other than TNF. The anti-IL-17 anti- ventional immunosuppressive drugs, Please address correspondence to: body secukinumab and the anti-IL-2 such as azathioprine, cyclosporine-A, Petros P. Sfikakis, MD, receptor antibody daclizumab were not cyclophosphamide and methotrexate, First Department of Propedeutic superior to placebo for ocular Behçet’s and Internal Medicine, are used either alone or in combination Laikon Hospital, in randomised controlled trials, com- for vital organ involvement. During the Athens University Medical School, prising 118 and 17 patients, respec- last decade there has been increased use Ag Thoma, 17, tively. The anti-IL-1 agents anakinra of anti-TNF monoclonal antibodies in GR-11527 Athens, Greece. and canakinumab and the anti-IL-6 patients with BD who were refractory E-mail: [email protected] agent tocilizumab were given to iso- to conventional treatment or developed Received on June 7, 2014; accepted in lated refractory disease patients, who life-threatening complications (4, 5). revised form on September 17, 2014. were either anti-TNF naïve (n=9) or Anti-TNF treatment has been shown to Clin Exp Rheumatol 2014; 32 (Suppl. 84): experienced (n=18).
    [Show full text]
  • Tocilizumab in the Treatment of Severe and Refractory Parenchymal Neuro
    TAB0010.1177/1759720X20971908Therapeutic Advances in Musculoskeletal DiseaseJ Liu, D Yan 971908research-article20202020 Therapeutic Advances in Musculoskeletal Disease Case Series Ther Adv Musculoskel Dis Tocilizumab in the treatment of severe and 2020, Vol. 12: 1–8 DOI:https://doi.org/10.1177/1759720X20971908 10.1177/ refractory parenchymal neuro-Behçet’s 1759720X20971908https://doi.org/10.1177/1759720X20971908 © The Author(s), 2020. Article reuse guidelines: syndrome: case series and literature review sagepub.com/journals- permissions Jinjing Liu* , Dong Yan*, Zhimian Wang, Yunjiao Yang, Shangzhu Zhang, Di Wu, Lingyi Peng, Zhichun Liu and Wenjie Zheng Abstract Correspondence to: Objectives: This study aimed to investigate the efficacy and safety of tocilizumab (TCZ) in Wenjie Zheng severe and refractory parenchymal neuro-Behçet’s syndrome (p-NBS). Department of Rheumatology and Clinical Methods: We retrospectively analyzed five patients with p-NBS treated with TCZ in our center Immunology, Peking Union between 2013 and 2020, and six cases from literature research with the index terms “neuro- Medical College Hospital, Chinese Academy of Behçet’s syndrome” and “tocilizumab” on PubMed NCBI. Medical Sciences & Peking Union Medical Results: A total of 11 patients with p-NBS were enrolled (5 males, 6 females), with a mean College, Key Laboratory of age of 34.5 ± 8.0 years at the onset. All the patients had parenchymal neurological lesions, Rheumatology and Clinical Rheumatology, Ministry six patients (54.5%) suffered from multiple lesions, and nine patients (81.8%) were disabled. of Education, National Clinical Research Center Before TCZ administration, all the patients had failed conventional therapy, eight patients for Dermatologic and (72.7%) received two or more immunosuppressants, and five patients showed insufficient Immunologic Diseases, No.
    [Show full text]
  • Sarcoidosis Manifesting During Treatment with Secukinumab for Psoriatic Arthritis Colm Kirby ‍ ‍ ,1 Darragh Herlihy,2 Lindsey Clarke,3 Ronan Mullan1
    Case report BMJ Case Rep: first published as 10.1136/bcr-2020-240615 on 22 February 2021. Downloaded from Sarcoidosis manifesting during treatment with secukinumab for psoriatic arthritis Colm Kirby ,1 Darragh Herlihy,2 Lindsey Clarke,3 Ronan Mullan1 1Rheumatology, Tallaght SUMMARY University Hospital, Dublin, Sarcoidosis is a multisystem inflammatory disorder Ireland 2 of uncertain aetiology. There are numerous case Radiology, Beaumont Hospital, reports of sarcoidosis occurring during treatment with Dublin, Ireland biological immunotherapies. Here, we describe the case 3Pathology, Tallaght University Hospital, Dublin, Ireland of a 52- year- old woman with psoriatic arthritis who developed multisystem sarcoidosis while being treated Correspondence to with secukinumab (anti-interleukin- 17A) therapy which, Dr Colm Kirby; to our knowledge, is the first such case. We discuss colmkirby11@ gmail. com existing literature and hypothesise that IL-17 blockade may precipitate the development of granulomatous Accepted 8 February 2021 disease. BACKGROUND Figure 1 (A) Palmar longitudinal view of dactylitic Sarcoidosis is a multisystem disorder characterised finger showing tendon sheath effusion with power by the presence of non-caseat ing granulomata. Doppler signal. (B) longitudinal view of posterior tibialis While the disease is most commonly character- tendon showing tendon sheath effusion, tenosynovial ised by thoracic adenopathy, lung parenchyma, thickening and power Doppler signal. skin and articular disease, all organ systems may be affected. While the precise aetiology of sarcoid- sedimentation rate (ESR) of 16 mm/hour (1–15), osis is unclear, numerous case reports of sarcoid- normal C- reactive protein (CRP) and normal osis occurring during the treatment with biological rheumatoid factor, anti- cyclic citrullinated peptide immunotherapies indicate that immune dysregula- (anti- CCP) and anti- neutrophil cytoplasm antibody tion plays a key role.
    [Show full text]
  • As Treatment for Refractory Acute Graft-Versus-Host Disease
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE Biology of Blood and Marrow Transplantation 12:1135-1141 (2006) provided by Elsevier - Publisher Connector ᮊ 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1211-0001$32.00/0 doi:10.1016/j.bbmt.2006.06.010 Encouraging Results with Inolimomab (Anti-IL-2 Receptor) as Treatment for Refractory Acute Graft-versus-Host Disease Jose Luis Piñana, David Valcárcel, Rodrigo Martino, M. Estela Moreno, Anna Sureda, Javier Briones, Salut Brunet, Jorge Sierra Division of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Universitat Autónoma de Barcelona, Barcelona, Spain Correspondence and reprint requests: David Valcárcel, Division of clinical Hematology, Hospital de la Santa Creu i Sant Pau, St Antoni Ma Claret 167, Barcelona 08021, Spain (e-Mail: [email protected]). Received September 16, 2005; accepted June 21, 2006 ABSTRACT Enlimomab, an anti-interleukin-2 receptor (anti-IL-2R) monoclonal antibody, may be useful in the treatment of steroid-refractory acute graft-versus-host disease (aGVHD) by inhibiting 1 of its putative immunopatho- genic pathways. We retrospectively analyzed 40 consecutive patients who received enlimomab as salvage treatment for steroid refractory aGVHD at a single institution between June 1999 and December 2004. Enlimomab was given intravenously at a dose of 11 mg/d for 3 consecutive days, followed by 5.5 mg/d for 7 consecutive days and then 5.5 mg every other day for 5 doses. No infusion-related side effects were noted. Twenty-three patients (58%) responded, including 15 (38%) complete and 8 (20%) partial responses.
    [Show full text]
  • Death from Mast Cell Leukemia: a Young Patient with Longstanding Cutaneous Mastocytosis Evolving Into Fatal Mast Cell Leukemia
    CASE REPORTS Pediatric Dermatology Vol. 29 No. 5 605–609, 2012 Death from Mast Cell Leukemia: A Young Patient with Longstanding Cutaneous Mastocytosis Evolving into Fatal Mast Cell Leukemia Rattanavalai Chantorn, M.D.,*, and Tor Shwayder, M.D. *Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, Department of Pediatric Dermatology, Henry Ford Hospital, Detroit, Michigan Abstract: Mastocytosis is a broad term used for a group of disorders characterized by accumulation of mast cells in the skin with or without extracutaneous involvement. The clinical spectrum of the disease varies from only cutaneous lesions to highly aggressive systemic involvement such as mast cell leukemia. Mastocytosis can present from birth to adult- hood. In children, mastocytosis is usually benign, and there is a good chance of spontaneous regression at puberty, unlike adult-onset disease, which is generally systemic and more severe. Moreover, individuals with systemic mastocytosis may be at risk of developing hematologic malignancies. We describe a girl who presented to us with a solitary mastocytoma at age 5 and later developed maculopapular cutaneous mastocytosis. At age 23, after an episode of anaphylactic shock, a bone marrow examination revealed mast cell leukemia. She ultimately died despite aggressive chemotherapy and bone marrow transplantation. Mastocytosis is characterized by the abnormal common forms of CM in childhood. The excoriation growth and infiltration of mast cells (MC) in various of lesions causes hives and perilesional erythema, tissues and is classified into two broad categories: which characterizes Darier’s sign (Fig. 3). SM is cutaneous mastocytosis (CM) and systemic mastocy- characterized by multifocal MC infiltrates with or tosis (SM) (1).
    [Show full text]
  • Acute Lymphocytic Leukemia Early Detection, Diagnosis, and Types Detection and Diagnosis
    cancer.org | 1.800.227.2345 Acute Lymphocytic Leukemia Early Detection, Diagnosis, and Types Detection and Diagnosis Catching cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that can be noticed, but that is not always the case. ● Can Acute Lymphocytic Leukemia (ALL) Be Found Early? ● Signs and Symptoms of Acute Lymphocytic Leukemia (ALL) ● Tests for Acute Lymphocytic Leukemia (ALL) Types of ALL Learn how ALL is classified and how this may affect your treatment options. ● Acute Lymphocytic Leukemia (ALL) Subtypes and Prognostic Factors Questions to Ask About ALL Here are some questions you can ask your cancer care team to help you better understand your ALL diagnosis and treatment options. ● Questions to Ask About Acute Lymphocytic Leukemia (ALL) 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 Can Acute Lymphocytic Leukemia (ALL) Be Found Early? For many types of cancers, finding the cancer early makes it easier to treat. The American Cancer Society recommends screening tests for early detection of certain cancers1 in people without any symptoms. But at this time there are no special tests recommended to detect acute lymphocytic leukemia (ALL) early. The best way to find leukemia early is to report any possible signs or symptoms of leukemia (see Signs and symptoms of acute lymphoblastic leukemia) to the doctor right away. For people at increased risk of ALL Some people are known to have a higher risk of ALL (or other leukemias) because of a genetic disorder such as Down syndrome, or because they were previously treated with certain chemotherapy drugs or radiation.
    [Show full text]
  • Solitary Plasmacytoma: a Review of Diagnosis and Management
    Current Hematologic Malignancy Reports (2019) 14:63–69 https://doi.org/10.1007/s11899-019-00499-8 MULTIPLE MYELOMA (P KAPOOR, SECTION EDITOR) Solitary Plasmacytoma: a Review of Diagnosis and Management Andrew Pham1 & Anuj Mahindra1 Published online: 20 February 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review Solitary plasmacytoma is a rare plasma cell dyscrasia, classified as solitary bone plasmacytoma or solitary extramedullary plasmacytoma. These entities are diagnosed by demonstrating infiltration of a monoclonal plasma cell population in a single bone lesion or presence of plasma cells involving a soft tissue mass, respectively. Both diseases represent a single localized process without significant plasma cell infiltration into the bone marrow or evidence of end organ damage. Clinically, it is important to classify plasmacytoma as having completely undetectable bone marrow involvement versus minimal marrow involvement. Here, we discuss the diagnosis, management, and prognosis of solitary plasmacytoma. Recent Findings There have been numerous therapeutic advances in the treatment of multiple myeloma over the last few years. While the treatment paradigm for solitary plasmacytoma has not changed significantly over the years, progress has been made with regard to diagnostic tools available that can risk stratify disease, offer prognostic value, and discern solitary plasmacytoma from quiescent or asymptomatic myeloma at the time of diagnosis. Summary Despite various studies investigating the use of systemic therapy or combined modality therapy for the treatment of plasmacytoma, radiation therapy remains the mainstay of therapy. Much of the recent advancement in the management of solitary plasmacytoma has been through the development of improved diagnostic techniques.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]